Table 3.
Study | Currency, year | Perspective | Effect | ΔC* | ΔE | Exact ICER* |
---|---|---|---|---|---|---|
Detemir versus NPH | ||||||
Valentine,54 2012 | Euro, 2010 | Public healthcare payer, Denmark | QALY | 68.35 | 0.02 | 3418 |
Euro, 2010 | Public healthcare payer, Sweden | QALY | 69.09 | 0.02 | 3455 | |
Euro, 2010 | Public healthcare payer, Finland | QALY | 88.04 | 0.02 | 4402 | |
Euro, 2010 | Healthcare payer, Netherlands | QALY | 63.24 | 0.02 | 3162 | |
Valentine,55 2011 | Swedish Krnor, 2006 | Public healthcare payer | QALY | 4329.38 | 0.53 | 8169 |
Swedish Krnor, 2006 | Public healthcare payer | Life years | 4329.38 | 0.14 | 30 924† | |
Cameron,5 2009 | Canadian, 2007 | Public healthcare payer | QALY | 3718.61 | 0.01 | 371 861 |
Gschwend,57 2009 | Euro, 2006 | Third party payer, Belgium | QALY | −18 300.85 | 0.52 | −35 194 |
Euro, 2006 | Third party payer, France | QALY | 435.22 | 0.55 | 791 | |
Euro, 2006 | Third party payer, Germany | QALY | −1308.74 | 0.45 | −2908 | |
Euro, 2006 | Third party payer, Italy | QALY | 2907.11 | 0.59 | 4927 | |
Euro, 2006 | Third party payer, Spain | QALY | −882.71 | 0.40 | −2207 | |
Tunis,58 2009 | Canadian dollars, 2007 | Public healthcare payer | QALY | 9935.13 | 0.48 | 20 698 |
Canadian dollars, 2007 | Public healthcare payer | Life years | 9935.13 | 0.05 | 198 703† | |
Glargine versus NPH | ||||||
Pfohl,53 2012 | Euro, 2010 | Public healthcare payer | QALY | −14 823 188.10 | 793 | −18 693 |
Euro, 2010 | Public healthcare payer | Life years | −14 823 188.10 | 392 | −37 914† | |
Cameron,5 2009 | Canadian dollars, 2007 | Public healthcare payer | QALY | 2930.21 | 0.04 | 73255 |
Greiner,56 2009‡ | CHF, 2006 | NR | QALY | 1437.71 | 0.24 | 5990 |
CHF, 2006 | NR | Life years | 1437.71 | 0.06 | 23 962 | |
Grima,59 2007 | Canadian dollars, 2005 | Public healthcare payer | QALY | 1426.06 | 0.07 | 20 372 |
Canadian dollars, 2005 | Public healthcare payer | Life years | 1426.06 | 0.08 | 17 826† | |
McEwan,60 2007 | UK pounds, 2005 | Public healthcare payer | 2534.14 | 0.13 | 19 493 | |
Glargine versus detemir | ||||||
Valentine,61 2006 | US dollars, 2005 | Societal | QALY | 6563.69 | −0.06 | −109 395 |
US dollars, 2005 | Societal | Life years | 6563.69 | −0.09 | −72 930† |
ΔC=difference in cost between treatment and control; ΔE=difference in effectiveness between treatment and control; ICER=incremental cost effectiveness ratio; NPH=neutral protamine Hagedorn; NR=not reported; QALY=quality adjusted life years.
*In US dollars, 2012.
†ICER was derived.
‡Unpublished data.